InterCure Reports Strong Preliminary 2025 Results with 11% Revenue Growth, Positive EBITDA, and Significant Cash Inflow

summarizeSummary

InterCure Ltd. announced preliminary estimated 2025 revenue of NIS 265 million, an 11% increase, alongside its twelfth consecutive half-year of positive Adjusted EBITDA and a strong cash position of NIS 43 million, bolstered by significant war-related compensation.

check_boxKey Events

• Strong Preliminary 2025 Financials

  Reported estimated annual revenue of NIS 265 million for 2025, an 11% increase from 2024, and achieved its twelfth consecutive half-year of positive Adjusted EBITDA.

• Robust Cash Position

  Ended 2025 with NIS 43 million in cash on hand, representing a strong liquidity position relative to its market capitalization.

• Significant War Compensation Received

  Received NIS 81 million in compensation advances from Israeli authorities for war-related damages, with a total claim of NIS 251 million pending.

• Strategic Growth and Market Expansion

  Generated first significant revenues from the German market, resumed production at the Nir Oz facility, and expanded through strategic partnerships and acquisitions of Botanico Ltd. and Cannasoul R&D Ltd.

auto_awesomeAnalysis

This filing indicates robust financial health and strategic progress for InterCure. The reported 11% revenue growth and consistent positive Adjusted EBITDA demonstrate operational efficiency and market traction. A particularly significant highlight is the NIS 43 million cash on hand, which represents a substantial portion of the company's market capitalization, providing strong liquidity. Furthermore, the receipt of NIS 81 million in war-related compensation advances is a major financial boost, significantly strengthening the balance sheet. The company's expansion into the German market and strategic acquisitions position it for continued international growth and enhanced capabilities. Investors should view these preliminary results and strategic developments as highly positive indicators for InterCure's future performance and stability.